```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, functions as a valuable scientific reagent extensively utilized in thrombosis studies . This Fab fragment selectively targets the glycoprotein IIb/IIIa complex on blood cells, blocking thrombus development. Consequently , it's often investigated as a technique to examine the processes underlying coagulation and to determine the effectiveness of anticoagulant therapies. Distribution is typically restricted to research settings.
```
The Abciximab Compound Research: Utilizing C7E3 Antibody and The 143653-53-6 Substance in Scientific Assessments
Ongoing investigation into abciximab, a platelet aggregation inhibitor, frequently incorporates the monoclonal protein C7E3 and the substance identified as 143653-53-6. These tools are essential for investigating abciximab's mode of function, evaluating its efficacy in different patient populations, and understanding potential indicators of treatment response. Additional study leveraging these particular reagents is likely to yield valuable data for improving patient care involving cardiovascular disease.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Investigating Research Possibilities with this Glycoprotein IIb/IIIa Inhibitor 143653-53-6 using C7E3
Recent work indicate that Abciximab (identified as 143653-53-6) presents significant research value, particularly when combined with a C7E3 construct. Preliminary findings indicated that this combination could boost clinical results in various heart-related settings. Further examination is focused on understanding the exact mechanism of action between Abciximab and C7E3, involving analysis of blood clot clumping and arterial preservation.
- Current study efforts aim to refine dosing strategies.
- Preclinical approaches are were employed to further validate such theories.
- Patient studies might be necessary to fully evaluate patient effectiveness.
```
Abciximab (C7E3) for Research: Quality and Characteristics (143653-53-6)
Researchers needing abciximab for laboratory research should carefully consider quality and defined parameters . This product is typically provided as a freeze-dried powder and comprehensive analytical data including identity by LC-MS, biological activity assays, and endotoxin level testing are available. Ensure the manufacturer's CoA clearly states defined values for impurities and meets relevant QC guidelines.
High-Purity ReoPro Details & Availability
Acquiring analytical-grade Abciximab, specifically referencing the molecule C7E3 and identified by the product number 143653-53-6, requires thorough consideration of its origin . This agent is frequently utilized in in vitro experiments, particularly those focused on platelet clumping and clotting . Available vendors offer this material in Abciximab reagent varying amounts , typically ranging from milligram to substantial bulk amounts . Please suggest reviewing the certificate of analysis to verify quality and appropriateness for your specific application . Moreover, confirm the stability date before purchasing to maintain optimal performance .
- Common Purity: >95%
- Keeping Conditions: -20°C and suitable conditions
- Intended Purpose: Platelet Adhesion Suppression Studies